Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is considered an independent risk factor for the development of cardiovascular disease. However, the association between changes in NAFLD status and the risk of cardiovascular disease (CVD) remains uncertain. Starting January 1, 2013, participants were followed until the occurrence of CVD event, death, or December 31, 2020. This was a population-based cohort study that included data from adults aged ≥ 20, who underwent 2 consecutive health screenings from 2009 to 2012. NAFLD was defined as a Fatty Liver Index ≥ 60 at each screening. The primary endpoint was a CVD event, which encompassed ischemic heart disease and cerebrovascular disease. The association between changes in NAFLD status and the risk of CVD was determined using multivariable Cox proportional hazards regression. This cohort comprised 4656,305 adults with a median age of 53 years. During 36,396,968 person-years of follow-up, 238,933 (5.1%) CVD events were observed. Compared to patients with no NAFLD at both screenings, patients who developed NAFLD at the second screening exhibited an increased risk of CVD (adjusted hazard ratio, 1.15; 95% confidence interval, 1.13-1.17). In contrast, individuals who recovered from NAFLD at the second screening demonstrated a reduced CVD risk compared to those with persistent NAFLD (adjusted hazard ratio, 0.91; 95% confidence interval, 0.90-0.92). The reversal of NAFLD is associated with a reduced risk of CVD. Therefore, focusing on NAFLD treatment could serve as a clinical target for lowering CVD risk.
Identifiants
pubmed: 37933021
doi: 10.1097/MD.0000000000035804
pii: 00005792-202311030-00053
pmc: PMC10627619
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e35804Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
LaBrecque DR, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467–73.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.
Singh SP, Singh A, Misra D, et al. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case–control study. J Clin Exp Hepatol. 2015;5:295–302.
Caballería L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol. 2010;22:24–32.
Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic fatty liver disease and the heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948–63.
Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.
Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–84.
Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51:728–36.
Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565–e1912565.
Cheol Seong S, Kim Y-Y, Khang Y-H, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46:799–800.
Son JS, Choi S, Kim K, et al. Association of blood pressure classification in Korean young adults according to the 2017 American College of Cardiology/American Heart Association Guidelines with subsequent cardiovascular disease events. JAMA. 2018;320:1783–92.
Lee J, Lee JS, Park S-H, et al. Cohort profile: the national health insurance service–national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46:e15–e15.
Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:1–7.
Liver EAftSoT, Diabetes EAftSo. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65–90.
Lee Y-H, Bang H, Park YM, et al. Non–laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One. 2014;9:e107584.
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.
Mahfood Haddad T, Hamdeh S, Anantha Narayanan M, et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a meta-analysis. Circulation. 2015;132(suppl_3):A14339–A14339.
Hu J, Xu Y, He Z, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2018;9:2752–60.
Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–53.
Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 2010;87:407–16.
DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227:429–36.
Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80.
Libby P, Everett BM. Novel antiatherosclerotic therapies. Arterioscler Thromb Vasc Biol. 2019;39:538–45.
Pacana T, Cazanave S, Verdianelli A, et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One. 2015;10:e0136822.
Shulman G. Ectopic fat in insulin resistance. Dyslipidemia, and Cardiometabolic Disease [accessed on 24 October 2017].
Coulon S, Francque S, Colle I, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012;59:442–9.
Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148–54.
Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506–14.
Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest. 2012;92:1428–39.
Stefan N, Häring H-U. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9:144–52.
Yoo HJ, Choi KM. Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab J. 2015;39:10–5.
Zhang Y, Yan J, Yang N, et al. High-level serum fibroblast growth factor 21 concentration is closely associated with an increased risk of cardiovascular diseases: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:705273.
Ke Y, Liu S, Zhang Z, et al. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis. 2021;20:55.
Polyzos SA, Kountouras J, Mavrouli M, et al. Selenoprotein P in patients with nonalcoholic fatty liver disease. Exp Clin Endocrinol Diabetes. 2019;127:598–602.
Liu S, Xiao J, Zhao Z, et al. Systematic review and meta-analysis of circulating fetuin-a levels in nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2021;9:3–14.
Yoo HJ, Hwang SY, Choi J-H, et al. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One. 2017;12:e0174717–e0174717.
Naito C, Hashimoto M, Watanabe K, et al. Facilitatory effects of fetuin-a on atherosclerosis. Atherosclerosis. 2016;246:344–51.
Cheng P, Zhang F, Yu L, et al. Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res. 2016;2016:1–8.
Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: deciphering communication from the liver. Mol Metab. 2021;44:101138.
Wei M, Liu J, Pan H, et al. Plasma Leukocyte Cell-Derived Chemotaxin 2 (LECT2) as a risk factor of coronary artery disease: a cross-sectional study. Angiology. 2021;73:265–74.
Saito Y, Sato N, Hirashima M, et al. Domain structure of bi-functional selenoprotein P. Biochem J. 2004;381:841–6.